These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28506134)

  • 1. Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe.
    Damjanov N; Karpati S; Kemeny L; Bakos N; Bobic B; Majdan M; Tlustochowicz W; Vitek P; Dokoupilova E; Aldinc E; Szumski A
    J Dermatolog Treat; 2018 Feb; 29(1):8-12. PubMed ID: 28506134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.
    Griffiths CE; Sterry W; Brock F; Dilleen M; Stefanidis D; Germain JM; Mallbris L
    Br J Dermatol; 2015 Jan; 172(1):230-8. PubMed ID: 24861696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
    Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
    BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.
    Boggs RL; Kárpáti S; Li W; Williams T; Pedersen R; Mallbris L; Gniadecki R
    BMC Dermatol; 2014 Aug; 14():14. PubMed ID: 25091090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
    Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
    Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
    Strohal R; Puig L; Chouela E; Tsai TF; Melin J; Freundlich B; Molta CT; Fuiman J; Pedersen R; Robertson D
    J Dermatolog Treat; 2013 Jun; 24(3):169-78. PubMed ID: 22251226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
    Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
    Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
    Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
    Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
    BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
    Papp KA; Barber K; Bissonnette R; Bourcier M; Lynde CW; Poulin Y; Shelton J; Toole J; Vieira A; Poulin-Costello M
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):361-366. PubMed ID: 24980988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
    Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
    Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
    Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Tsuji W
    Arthritis Rheum; 2004 Jul; 50(7):2264-72. PubMed ID: 15248226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic Drugs.
    Behrens F; Meier L; Prinz JC; Jobst J; Lippe R; Löschmann PA; Lorenz HM
    J Rheumatol; 2018 Jun; 45(6):802-810. PubMed ID: 29606665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.
    Thaçi D; Galimberti R; Amaya-Guerra M; Rosenbach T; Robertson D; Pedersen R; Yang S; Kuligowski M; Boggs R
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):900-6. PubMed ID: 23848989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis.
    Puig L; Strohal R; Husni ME; Tsai TF; Noppakun N; Szumski A; Yang S; Robertson D; Boggs R; Koenig AS
    J Dermatolog Treat; 2015 Feb; 26(1):7-15. PubMed ID: 24283931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.